Search

Displaying results 381 - 390 of 1804 in total
  1. Drug

    Drotaverine

    go.drugbank.com/drugs/DB06751
    ApprovedWithdrawn

    Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than pa...

  2. Drug

    Dextrothyroxine

    go.drugbank.com/drugs/DB00509
    ApprovedWithdrawn

    Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin.

  3. Drug

    Mitomycin

    go.drugbank.com/drugs/DB00305
    ApprovedInvestigational

    [A193419] Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. … [A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper

    Products: MIXANDEX PISA
  4. Drug

    Chromium

    go.drugbank.com/drugs/DB11136
    ApprovedInvestigational

    Humans can be exposed to chromium via ingestion, inhalation, and dermal or ocular exposure [L1983].

    Mixtures: Vita Balance 2000, Super Vita-vim With Beta-carotene - Tab
  5. Drug

    Clofazimine

    go.drugbank.com/drugs/DB00845
    ApprovedInvestigationalWithdrawn

    Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye -...

  6. Drug

    Famtozinameran

    go.drugbank.com/drugs/DB17088
    ApprovedInvestigational

    The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). ...

  7. Target

    Prostacyclin receptor

    go.drugbank.com/bio_entities/BE0000475
    TargetHumans

    Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase

    Polypeptides: Prostacyclin receptorSynonyms: PGI receptor, PGI2 receptor
  8. Target

    Glucagon receptor

    go.drugbank.com/bio_entities/BE0000527
    TargetHumans

    G protein-coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. … Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system

    Polypeptides: Glucagon receptorFunction: glucagon receptor activity
  9. Target

    Erythropoietin receptor

    go.drugbank.com/bio_entities/BE0000654
    TargetHumans

    Receptor for erythropoietin, which mediates erythropoietin-induced erythroblast proliferation and differentiation (PubMed:10388848, PubMed:2163695, PubMed:2163696, PubMed:8662939, PubMed:9774108).

    Polypeptides: Erythropoietin receptorFunction: erythropoietin receptor activity
  10. Target

    Nociceptin receptor

    go.drugbank.com/bio_entities/BE0002378
    TargetHumans

    G protein-coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. … Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity.

    Polypeptides: Nociceptin receptorSynonyms: Orphanin FQ receptor, Kappa-type 3 opioid receptor